Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 3.23 USD Market Closed
Market Cap: 554.3m USD
Have any thoughts about
Savara Inc?
Write Note

Savara Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Savara Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Savara Inc
NASDAQ:SVRA
Total Receivables
$1.2m
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Savara Inc
Glance View

Market Cap
551.8m USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
2.14 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Savara Inc's Total Receivables?
Total Receivables
1.2m USD

Based on the financial report for Sep 30, 2024, Savara Inc's Total Receivables amounts to 1.2m USD.

What is Savara Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
-4%

Over the last year, the Total Receivables growth was 16%. The average annual Total Receivables growth rates for Savara Inc have been -1% over the past three years , -4% over the past five years .

Back to Top